Berenberg Sees 25% Upside in Eli Lilly as Obesity Drugs Keep Winning
Berenberg upgraded Eli Lilly from Hold to Buy and lifted its target to $1,400, citing obesity-drug leadership and a likely 2026 guidance beat.
/ 1642 items
#XY↓
Vera’s Trutakna Slows Kidney Decline in Two-Year IgAN Trial
Vera’s Trutakna kept kidney function nearly stable over two years in IgAN, cut serious progression risk, and will support a full FDA filing.
Veracyte Buys Convergent Genomics for Up to $180 Million, Adding a Urine Test for Bladder Cancer
Veracyte acquired Convergent Genomics for $150M cash plus up to $30M in milestones, adding UroAmp, a urine tumor DNA test for bladder cancer.
Sionna Moves SION-451 + SION-2222 Into Phase 2a After August Setback
Sionna will start a Q1 2027 Phase 2a trial of SION-451 plus SION-2222 after a missed Trikafta add-on study. A 46% staff cut extends cash into 2H 2029.
Cellectis Drops Blood-Cancer CAR-Ts; Citizens Cuts Rating
Citizens cut Cellectis to Market Perform after it scrapped allogeneic CAR-T programs and pivoted to in-vivo gene editing for high triglycerides and cholesterol. Catalysts now 2027–28.
Contineum’s J&J-Partnered Depression Drug Misses Phase 2 Goal
Contineum said its J&J-partnered drug PIPE-307 missed the Phase 2 primary goal of improving MADRS scores at Day 5 versus placebo.